REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma—A quality-adjusted time without symptoms of progression or toxicity analysis

Cancer

Volumn 123, Issue 12, 2017, Pages 2294-2302

  Berry, Vincent ^a,b   Basson, Laurent ^a   Bogart, Emilie ^a   Mir, Olivier ^c   Blay, Jean Yves ^d   Italiano, Antoine ^e   Bertucci, François ^f   Chevreau, Christine ^g   Clisant Delaine, Stéphanie ^a,b   Liegl Antzager, Bernadette ^h   Tresch Bruneel, Emmanuelle ^a   Wallet, Jennifer ^a   Taieb, Sophie ^a   Decoupigny, Emilie ^a,b   Le Cesne, Axel ^c   Brodowicz, Thomas ⁱ   Penel, Nicolas ^a,b  

^a CENTRE OSCAR LAMBRET   (France)

^b Methodology and Clinical Research Platform   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT BERGONIÉ   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g University Institute of Cancer Oncopole   (France)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY OF VIENNA   (Austria)

Author keywords

metastatic soft tissue sarcoma; placebo; quality adjusted survival; quality adjusted time without symptoms of progression or toxicity (Q TWiST); regorafenib

Indexed keywords

DOXORUBICIN; PLACEBO; REGORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER RECURRENCE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SOFT TISSUE SARCOMA; TUMOR GROWTH; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; FECES INCONTINENCE; HAND-FOOT SYNDROME; HOSPITALIZATION; LEIOMYOSARCOMA; LIPOSARCOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; SARCOMA; SARCOMA, SYNOVIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC AGENTS; ASTHENIA; DIARRHEA; DOUBLE-BLIND METHOD; FECAL INCONTINENCE; FEMALE; HAND-FOOT SYNDROME; HOSPITALIZATION; HUMANS; HYPERTENSION; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; MUCOSITIS; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; QUALITY OF LIFE; SARCOMA; SARCOMA, SYNOVIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85020268203     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30661     Document Type: Article

References (13)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294.
2. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii102-iii112.
3. Italiano A, Mathoulin-Pelissier S, Le Cesne A, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049-1054.
4. Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29:2528-2533.
5. Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:1732-1742.
6. Reichardt P, Leahy M, Garcia Del Muro X, et al. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study. Sarcoma. 2012;2012:740279.
7. Coens C, Vand der Graaf WT, Blay JY, et al. Health-related quality-of-life results from PALETTE : a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease progressed during or after prior chemotherapy—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Global Network study (EORTC 62072). Cancer. 2015;121:2933-2941.
8. Gough NJ, Smith C, Ross JR, Riley J, Judson I. Symptom burden, survival and palliative care in advanced soft tissue sarcoma. Sarcoma. 2011;2011:325189.
9. Patil S, Figlin RA, Hutson TE, et al. Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α. Br J Cancer. 2012;106:1587-1590.
10. Beaumont JL, Salsman JM, Diaz J, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122:1108-1115.
11. Van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind placebo-controlled phase 3 trial. Lancet. 2012;379:1879-1886.
12. Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R. Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma. 2013;2013:863056.
13. Shingler SL, Swinburn P, Lloyd A, et al. Elicitation of health state utilities in soft tissue sarcoma. Qual Life Res. 2013;22:1697-1706.